MedPath

Effectiveness of a social cognition treatment (T-ScEmo) in patients with moderate to severe traumatic brain injury

Not Applicable
Completed
Conditions
Traumatic brain injury in the subacute and chronic phase of recovery, with deficits in social cognition
Nervous System Diseases
Registration Number
ISRCTN81350364
Lead Sponsor
Hersenstichting Nederland (Dutch Brain Foundation)
Brief Summary

2017 results in https://pubmed.ncbi.nlm.nih.gov/28786854/ (added 27/11/2020)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
61
Inclusion Criteria

1. Moderate to severe traumatic brain injury
2. Sub-acute or chronic stage of recovery
3. Referred on clinical grounds, that is, being identified as having changes in social functioning, with at least 1 deficit in social cognition tests and/or proxy ratings on the BAFQ-social monitoring and/or empathy scale>10
4. Orbitofrontal/medioprefrontal brain damage demonstrated with MRI
5. Presence of a proxy to fill in questionnaires

Exclusion Criteria

1. Neurodegenerative or psychiatric illness
2. Severe cognitive impairment that would preclude treatment (i.e. amnestic syndrome, global aphasia, neglect)
3. Very severe behavioral regulation deficits for which continuous external control was needed and/or physical aggressiveness
4. Severe depression

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement of social cognition (pre- to postmeasurement) on the Awareness of Social Inferences Test (TASIT-short) at baseline, within 2 weeks of the last treatment session and at 3-5 monts follow up.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath